Pembrolizumab & ICE for Hodgkin lymphoma

1 Views

07/15/23

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines important updates in Hodgkin lymphoma from the 2021 ASH conference. Dr Collins draws focus to the use of checkpoint inhibition for the treatment of Hodgkin lymphoma. In this video, Dr Collins discusses a presentation on the use of pembrolizumab, a PD-1 inhibitor, combined with ICE chemotherapy. Preliminary findings in this study included a good response rate in patients, high and durable progression-free survival (PFS), and no impairment of stem cell collection. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.